openPR Logo
Press release

Worldwide Sales of Lung Cancer Therapeutics are predicted to increase at a CAGR of 15.0% during the forecast period - Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca

06-16-2023 12:19 PM CET | Health & Medicine

Press release from: Global Insight Services

Lung Cancer Therapeutics Market

Lung Cancer Therapeutics Market

The global lung cancer therapeutics market was valued at USD 18.3 billion in 2021 and it is anticipated to grow further till USD 74.1 billion by 2031, at a CAGR of 15.0% during the forecast period.

To Remain 'Ahead' Of Your Competitors, Request for A Sample - https://www.globalinsightservices.com/request-sample/GIS10320

The uncontrolled proliferation of cells in the lung tissues causes lung cancer, a deadly lung tumor. The main risk factor for lung cancer development is cigarette smoking. Lung cancer can also be brought on by smoking tobacco for a long time. Using bronchoscopy or CT guidance, a biopsy is performed to confirm the diagnosis of lung cancer. Therefore, chemotherapy, radiation, immunotherapy, surgery, etc. can all be used to treat lung cancer.

Market Trends and Drivers

Rising cancer awareness in both developed and developing countries, the introduction of new medical diagnostic tools and cutting-edge treatments, and an increase in lung cancer diagnoses have all contributed to the market expansion for lung cancer medicines.

Read More Report of Lung Cancer Therapeutics Market: https://www.globalinsightservices.com/reports/lung-cancer-therapeutics-market/

The expansion of the global market is also being boosted by this, along with rising investments made by leading players in research and development activities. Due to an increase in lung cancer cases, more attention is being paid to R&D projects, which is what is causing the market to alter.

Get a customized scope to match, your need ask an expert - https://www.globalinsightservices.com/request-customization/GIS10320

Global Lung Cancer Therapeutics Market Segmentation

By Therapy

Targeted Therapy
Immunotherapy
Chemotherapy

By Cancer Type

Non-small Cell Lung Cancer
Small Cell Lung Cancer

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

For In-Depth Competitive Analysis, Purchase this Report - https://www.globalinsightservices.com/checkout/single_user/GIS10320

Major Players in the Global Lung Cancer Therapeutics Market

The key players studied in the report are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Astellas, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), and Merck Sharp & Dohme Corp. among others.

New Report Published by Global Insight Services: https://www.globalinsightservices.com/reports/hydrogen-projects-database/

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Worldwide Sales of Lung Cancer Therapeutics are predicted to increase at a CAGR of 15.0% during the forecast period - Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca here

News-ID: 3091784 • Views:

More Releases from Global Insight Services

Glp-1 Agonist Market To Surge From $53 BN To $264.9 BN By 2034 At 17.5% Cagr. Key Players: Hanmi Pharmaceutical, Zydus Cadila, Oramed Pharmaceuticals.
Glp-1 Agonist Market To Surge From $53 BN To $264.9 BN By 2034 At 17.5% Cagr. Ke …
Market Overview GLP-1 Agonist Market is rapidly evolving as the demand for advanced diabetes and obesity treatments continues to rise globally. These drugs, known as glucagon-like peptide-1 receptor agonists, help improve insulin secretion, reduce glucagon levels, and enhance satiety-making them a powerful solution for type 2 diabetes and weight management. With diabetes and obesity reaching unprecedented levels, the GLP-1 Agonist Market stands at the forefront of therapeutic innovation. Growing patient awareness,
Financial Risk Management Software Market To Grow From $24.5 BN To $47.8 BN By 2034 At 6.9% Cagr. Key Players: Activeviam, Sas Risk Management, Fiserv.
Financial Risk Management Software Market To Grow From $24.5 BN To $47.8 BN By 2 …
Market Overview Financial Risk Management Software Market is evolving rapidly as financial institutions and enterprises navigate increasingly complex global uncertainties. With tightening regulations and growing exposure to market volatility, organizations are turning toward advanced digital solutions that help identify, assess, and mitigate financial risks in real time. The Financial Risk Management Software Market integrates AI, machine learning, predictive analytics, and cloud technologies to enhance credit, liquidity, operational, and market risk insights.
Esg Risk Management Market To Rise From $268.8 MN To $1,032.2 MN By 2034 At 14.4% Cagr. Key Players: Sustainalytics, Reprisk, Arabesque.
Esg Risk Management Market To Rise From $268.8 MN To $1,032.2 MN By 2034 At 14.4 …
Market Overview ESG Risk Management Market is gaining significant momentum as businesses increasingly prioritize sustainability and ethical governance in their operations. Valued at $268.8 million in 2024, the market is projected to surge to $1,032.2 million by 2034, growing at a CAGR of 14.4%. The ESG Risk Management Market encompasses technologies and services designed to identify, monitor, and mitigate environmental, social, and governance risks, ensuring businesses operate responsibly while complying with
Enterprise Firewall Market To Grow From $15 BN (2024) To $40.3 BN (2034) At 10.4% Cagr. Key Players: Sonicwall, Watchguard, Palo Alto Networks.
Enterprise Firewall Market To Grow From $15 BN (2024) To $40.3 BN (2034) At 10.4 …
Market Overview Enterprise Firewall Market is witnessing substantial growth as organizations worldwide prioritize safeguarding their digital infrastructure from sophisticated cyber threats. Valued at $15 billion in 2024, the market is projected to reach $40.3 billion by 2034, expanding at a CAGR of 10.4%. The Enterprise Firewall Market encompasses solutions designed to secure enterprise networks by monitoring, filtering, and blocking unauthorized access while ensuring uninterrupted business operations. With the surge in cyberattacks,

All 5 Releases


More Releases for Lung

Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: Core Growth Enabler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Lung Cancer Drugs Industry Market Size Be by 2025? The market for lung cancer medications has seen a swift expansion in previous years. The market size is projected to escalate from $47.94 billion in 2024 to $54.13 billion in 2025, with a compound annual growth rate
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: An Emerging Driver …
The Lending And Payments Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Lending And Payments Market? The lending and payments market has experienced strong growth in recent years. It is set to rise from $12,326.44 billion in 2024 to
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market? The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market? The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and
Lung Cancer Screening Market - Empowering Proactive Lung Health: The Future of C …
Newark, New Castle, USA: The "Lung Cancer Screening Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Lung Cancer Screening Market: https://www.growthplusreports.com/report/lung-cancer-screening-market/7787 This latest report researches the industry structure,
Artificial Lung Market May Set New Growth Story | Breethe, Lung Biotechnology, M …
A new research document is added in HTF MI database of 37 pages, titled as 'Artificial Lung - Medical Devices Pipeline Assessment, 2020' with detailed analysis, Competitive landscape, forecast and strategies. The study covers important players/vendors such as ALung Technologies Inc, Breethe, Inc., Case Western Reserve University, Lung Biotechnology PBC, MC3 Inc, McGowan Institute for Regenerative , Medicine, Miromatrix Medical Inc, The Charles Stark Draper Laboratory Inc, U.S. Ann Arbor